通过天眼查大数据分析，山东新华制药股份有限公司共对外投资了19家企业，参与招投标项目5000次， 知识产权方面有商标信息402条，专利信息524条，此外企业还拥有行政许可855个。 来源：金融界 新华制药最新一期业绩显示，截至2025一季报，公司营业总收入24.30亿元、同比减少1.81%，归属净利 润1.12亿元，同比减少20.99%，扣非净利润1.05亿元，同比减少23.74%，流动比率1.236、速动比率 0.872、资产负债率41.86%。 天眼查商业履历信息显示，山东新华制药股份有限公司，成立于1998年，位于淄博市，是一家以从事医 药制造业为主的企业。企业注册资本689776.535万人民币，实缴资本68240.7635万人民币。公司法定代 表人为贺同庆。 金融界消息 截至2025年8月15日收盘，新华制药（000756）报收于16.44元，上涨1.11%，换手率 2.24%，成交量11.05万手，成交金额1.81亿元。 资金流向方面，今日主力资金净流出1941.19万元，占比成交额10.74%。其中，超大单净流出1021.86万 元、占成交额5.66%，大单净流出919.33万元、占成交额5.0 ...

金融界消息 截至2025年8月14日收盘，新华制药（000756）报收于16.26元，下跌2.22%，换手率 2.72%，成交量13.41万手，成交金额2.20亿元。 资金流向方面，今日主力资金净流出4119.96万元，占比成交额18.7%。其中，超大单净流出2607.20万 元、占成交额11.84%，大单净流出1512.77万元、占成交额6.87%，中单净流出流入747.13万元、占成交 额3.39%，小单净流入3372.84万元、占成交额15.31%。 新华制药最新一期业绩显示，截至2025一季报，公司营业总收入24.30亿元、同比减少1.81%，归属净利 润1.12亿元，同比减少20.99%，扣非净利润1.05亿元，同比减少23.74%，流动比率1.236、速动比率 0.872、资产负债率41.86%。 天眼查商业履历信息显示，山东新华制药股份有限公司，成立于1998年，位于淄博市，是一家以从事医 药制造业为主的企业。企业注册资本689776.535万人民币，实缴资本68240.7635万人民币。公司法定代 表人为贺同庆。 通过天眼查大数据分析，山东新华制药股份有限公司共对外投资了19家企业，参与招投标 ...

Group 1 - The company, Shandong Xinhua Pharmaceutical Co., Ltd. (00719.HK), will hold a board meeting on August 26, 2025, at 9:30 AM in Zibo, Shandong Province, China [1] - The agenda includes the review and approval of the company's unaudited interim results for the six months ending June 30, 2025 [1] - Other matters may also be discussed during the meeting, if applicable [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之任何 損失承擔任何責任。 山東新華製藥股份有限公司 Shandong Xinhua Pharmaceutical Company Limited （於中華人民共和國註冊成立之股份有限公司） （股份代碼：00719） 執行董事： 賀同慶先生（董事長） 徐文輝先生 侯 寧先生 獨立非執行董事： 潘廣成先生 朱建偉先生 淩沛學先生 張菁菁女士 董事會會議通知 山東新華製藥股份有限公司（「本公司」）董事會（「董事會」）宣佈，本公司將於二零二五年 八月二十六日（星期二）上午九時三十分在中華人民共和國（「中國」）山東省淄博市高新區 魯泰大道1號本公司會議室召開董事會會議，會議內容如下： 承董事會命 山東新華製藥股份有限公司 賀同慶先生 董事長 中國 淄博，二零二五年八月十二日 於本公告日期，本公司董事會由下列董事組成： 公告 非執行董事： 徐 列先生 張成勇先生 1、 審議及批准本公司及其附屬公司截至二零二五年六月三十日止六個月未經審計的中期 ...

Group 1 - The total salary scale of CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average annual salary of 814,800 yuan [1][2] - Among the CFOs, those aged 40-50 constitute the majority at 36%, while 5% are over 60 years old, 33% are aged 50-60, and 26% are 40 years old or younger [1] - The educational background of CFOs shows that 65% hold a bachelor's degree, 21% have a master's degree, 12% have an associate degree, and only 2% have a high school education [1] Group 2 - The average annual salary of CFOs in the A-share raw material pharmaceutical companies is 661,200 yuan [2] - The distribution of salaries indicates that 44% of CFOs earn below 500,000 yuan, 44% earn between 500,000 and 1 million yuan, and 12% earn above 1 million yuan [2] - The top three highest-paid CFOs are Gong Yuda from Guobang Pharmaceutical at 1.93 million yuan, Li Qirong from Zhejiang Pharmaceutical at 1.84 million yuan, and Hou Ning from Xinhua Pharmaceutical at 1.57 million yuan [2]

Core Viewpoint - Xinhua Pharmaceutical's stock price decreased by 1.71% to 16.69 yuan, with a trading volume of 190,900 hands and a transaction amount of 321 million yuan [1] Company Overview - Xinhua Pharmaceutical is primarily engaged in the research, production, and sales of chemical raw materials, formulations, and pharmaceutical intermediates, covering various therapeutic areas including antipyretic and analgesic, cardiovascular, anti-infection, and nervous system [1] Recent Developments - On August 5, the company announced that its wholly-owned subsidiary, Xinda Pharmaceutical, received approval from the National Medical Products Administration for the registration certificate of Finasteride tablets, which are used to treat benign prostatic hyperplasia and are classified as a Category B drug under medical insurance [1] - Public data indicates that the sales revenue of this drug in Chinese public medical institutions is expected to be approximately 1.45 billion yuan in 2024 [1] Financial Flow - On the day of the stock price decline, the net outflow of main funds for Xinhua Pharmaceutical was 26.63 million yuan, with a cumulative net outflow of 90.37 million yuan over the past five days [1]

Core Viewpoint - Xinhua Pharmaceutical (000756) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the drug registration certificate for Finasteride tablets from the National Medical Products Administration [1] Company Summary - Xinhua Pharmaceutical's subsidiary has successfully obtained regulatory approval for Finasteride tablets, indicating a significant milestone in expanding its product portfolio [1]

Core Insights - Xinhua Pharmaceutical's revenue composition for 2024 is as follows: 48.1% from chemical drug formulation manufacturing, 32.32% from chemical raw material manufacturing, and 19.59% from pharmaceutical intermediates and others [1]. Group 1 - Xinhua Pharmaceutical announced the approval of Finasteride tablets by the National Medical Products Administration [3]. - The product name for the newly approved drug is "Finasteride Tablets" [3].

Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration certificate of Finasteride tablets, which are indicated for the treatment and management of benign prostatic hyperplasia (BPH) [1] Group 1 - The approved Finasteride tablets are designed to treat and control BPH and to prevent urinary system events, including reducing the risk of acute urinary retention [1] - The medication can help shrink enlarged prostates, improve urinary flow, and alleviate symptoms associated with prostatic hyperplasia [1]

山东新华制药股份有限公司 关于子公司获得非那雄胺片药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或重大遗漏。 证券代码：000756 证券简称：新华制药 公告编号：2025-45 药品批准文号：国药准字H20255064 近日，山东新华制药股份有限公司之全资子公司山东淄博新达制药有限公司（以下简称 "新达制药"）收到国家药品监督管理局核准签发的非那雄胺片（以下简称"本品"）《药品 注册证书》。现将相关情况公告如下： 一、基本情况 药品名称：非那雄胺片 剂型：片剂 规格：5mg 药品分类：处方药 注册分类：化学药品4类 申请人：山东淄博新达制药有限公司 申请事项：境内生产药品注册上市许可 受理号：CYHS2400153 通知书编号：2025S02419 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注 册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、标签及生产工艺照所附 执行。药品生产企业应当符合药品生产质量管理规范要求方可生产销售。 二、其他相关信息 2024年1月，新达制药向国家药品监督管理局CDE递交非那雄胺 ...